NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Danicopan
Other: Placebo
Drug: Remdesivir

First Posted Date: 2021-08-03

Last Posted Date: 2023-06-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 201

Registration Number: NCT04988035

Locations: 🇺🇸
Great Lakes Clinical Trials, Chicago, Illinois, United States
🇺🇸
Nuvance Health Danbury Hospital - Infectious Disease, Danbury, Connecticut, United States
🇺🇸
Kern Medical Center, Bakersfield, California, United States

and more 36 locations

The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

Phase 2

Completed

Conditions: Systemic Allergic Reaction

Interventions: Biological: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)
Other: Placebo
Biological: Pfizer-BioNTech COVID-19 Vaccine, Bivalent

First Posted Date: 2021-07-27

Last Posted Date: 2023-10-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 20

Registration Number: NCT04977479

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: Influenza RG-A/Texas/71/2017 (H3N2) Challenge
Other: Placebo

First Posted Date: 2021-07-27

Last Posted Date: 2023-12-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 60

Registration Number: NCT04978454

Locations: 🇺🇸
Duke University Trent Drive, Durham, North Carolina, United States
🇺🇸
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States

Community Dynamics of Malaria Transmission in Humans and Mosquitoes at Maferinyah Sub-Prefecture, Guinea

Completed

Conditions: Malaria

First Posted Date: 2021-07-21

Last Posted Date: 2024-10-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 400

Registration Number: NCT04969913

Locations: 🇺🇸
Immunology and Pathogenesis Laboratories, Bethesda, Maryland, United States
🇬🇳
Maferinyah Rural Health Training and Research Center, Maferinyah, Guinea

COVID-19 Protection After Transplant Pilot Study

Phase 2

Completed

Conditions: Kidney Transplant Recipients

Interventions: Biological: mRNA-1273 vaccine (Moderna)
Biological: BNT162b2 vaccine (Pfizer/BioNTech)

First Posted Date: 2021-07-20

Last Posted Date: 2024-10-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 81

Registration Number: NCT04969263

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Vaccination for Recovered Inpatients With COVID-19 (VATICO)

Phase 4

Completed

Conditions: Covid19

Interventions: Biological: Moderna mRNA-1273 COVID-19 vaccine
Biological: Pfizer BNT162b2 COVID-19 vaccine

First Posted Date: 2021-07-20

Last Posted Date: 2024-03-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 66

Registration Number: NCT04969250

Locations: 🇺🇬
Lira Regional Referral Hospital (Site 634-605), Plot 9/19, 21-41 Ngetta Road Police Road, Lira, Uganda
🇺🇸
The Miriam Hospital (Site 080-039), 164 Summit Ave., Providence, Rhode Island, United States
🇺🇸
San Francisco VAMC (Site 074-002), 4150 Clement Street, San Francisco, California, United States

and more 27 locations

Natural History of Systemic and Nasal Mucosal Immunity After Influenza Vaccination in a Pediatric Population

Completed

Conditions: Influenza Immunity

First Posted Date: 2021-07-15

Last Posted Date: 2024-02-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 65

Registration Number: NCT04963166

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine

Phase 1

Terminated

Conditions: H3N2 Influenza

Interventions: Other: Placebo
Biological: Sing2016 M2SR H3N2

First Posted Date: 2021-07-13

Last Posted Date: 2024-05-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 140

Registration Number: NCT04960397

Locations: 🇺🇸
University of Iowa - Infectious Disease Clinic, Iowa City, Iowa, United States
🇺🇸
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States
🇺🇸
Duke Vaccine and Trials Unit, Durham, North Carolina, United States

and more 1 locations

SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine

Phase 4

Completed

Conditions: SARS-CoV2 Infection
Covid19

Interventions: Biological: Study-provided Moderna mRNA-1273 COVID-19 vaccine
Biological: Community-provided Moderna mRNA-1273 COVID-19 Vaccine
Biological: Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine

First Posted Date: 2021-07-07

Last Posted Date: 2023-05-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 43

Registration Number: NCT04952402

Locations: 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸
Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS, Boston, Massachusetts, United States
🇺🇸
University of Washington AIDS CRS, Seattle, Washington, United States

and more 3 locations

PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia

Active, not recruiting

Conditions: HIV
Tuberculosis

First Posted Date: 2021-06-15

Last Posted Date: 2024-12-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 200

Registration Number: NCT04926922

Locations: 🇱🇷
Duport Road Clinic, Monrovia, Liberia
🇺🇸
National Institutes of Health Cinical Center, Bethesda, Maryland, United States
🇱🇷
C.H. Rennie Hospital, Kakata, Liberia

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy